The imaging company’s newly launched division, created to produce drug ingredients, received the loan from the US International Development Finance Corp.
Thousand Oaks Biopharmaceuticals raised $45m in Series A financing, enabling the company to expand its CDMO and CMC services as well as its capabilities in global biologics development.
Encouraged by a North Carolina state grant, Fresenius Kabi will expand its prefilled syringes business acquired from Becton, Dickinson and Company in 2016.
Helomics Corporation and Pittsburgh Life Sciences Greenhouse (PLSG) have collaborated to form a biotechnology incubator with a precision and diagnostics medicine focus.
The global central laboratory and support services provider has secured a $24.5m Series A investment and is on track to double in size, again, over the next five years, says CEO.
Atlas Genetics has said it will expand manufacturing capacity for cartridge-based STI tests at a UK facility owned by drug delivery technology firm Bespak Europe ltd.
Fresenius Kabi has said it will increase manufacturing capacity and create jobs at a site in Illinois in a move that will earn the German firm US tax breaks.
For the third year in a row, about 30% of Deloitte poll respondents say their companies experienced supply chain fraud, waste, or abuse in the previous year.
The UK’s Biomedical Catalyst funding scheme encourages investors to back innovative biopharma research and should be continued according to the BioIndustry Association (BIA).
Investor backing puts transparency on the pharma agenda says SenseAboutScience, even though none of the funds pledging support for Alltrials have committed to pull investment from drug firms that disagree.
China-based contract research and manufacturing company WuXi PharmaTech has received a proposal to be taken private by a consortium led by its CEO and Ally Bridge Group Capital Partners.
With sky-high valuations and soaring M&A prices, the question of whether there’s a biotech bubble continues to crop up, though now some analysts are saying this so-called bubble and its inevitable pop may be a cause for concern for CROs (contract...
China-based CRO WuXi PharmaTech has entered into a syndicated loan facility to borrow up to $165m from a consortium of banks in Asia to seek out new acquisitions.
Biopharma companies are not likely to outsource a larger chunk of their manufacturing than they have in the past 10 years, according to a new report from PharmSource.
Clinverse, a provider of automated financial management tech solutions for clinical trials, has closed a $9.1m (€6.9m) round of funding led by New Jersey-based Edison Partners.
Biopharma firms continued to attract US venture capital investment in Q1 according to new analysis by PricewaterhouseCoopers (PwC), which says the number of firms that received backing is encouraging.
The UK Government has set out to make Britain a more attractive place from which to source drugs and ingredients by awarding a series of taxpayer funded grants to supply chain focused innovation projects.
Parexel has received $100m from the sale of notes with a group of institutional investors as part of plans to finance new acquisitions and pay down outstanding debt.
Indian contract manufacturer Surya Pharmaceutical has received an EDQM Certificate of Suitability (CEP) for an antibiotic API and approval for its Banur plant from Teva.
PPD posted an improved set of financials for Q2 days after announcing a review of its long-term plan and capital structure following speculation it was looking for a buyer.
Cytovance Biologics, the US-based biopharmaceutical contract manufacturer (CMO), has secured a growth equity investment from Connecticut, US-based private investors, Great Point Partners.
The US contract research organization (CRO) Quintiles may look at acquisitions and more ‘strategic partnerships’ after securing a $2.43bn credit facility.
West Pharmaceutical Services will invest $29m to expand its syringe plungers and intravenous (IV) system components facility in Kinston, North Carolina, in the US.
Ugandan drugmaker Quality Chemicals Industries (QCI) will invest $80m in manufacturing operations to boost capacity for the production of generic AIDS and malaria drugs.
TetraLogic Pharmaceuticals receives $5m (€3.7m) investment from Pfizer Ventures, helping fund clinical development of a drug that mimics naturally forming proteins, promoting cell death.
A consortium including GlaxoSmithKline and GEA has been formed to push continuous processing and improve pharma manufacturing efficiency in the UK in response to competition from emerging markets.
US CRO and central laboratory services provider Pacific Biometrics (PBI) has entered into a $4m (€2.7m) loan agreement that it says will help further the development of its contract biomarkers business.
Creative thinking is required by biotechs if they are to stay afloat despite the lack of funding, according to a report by Ernst & Young, and this could reshape the landscape of the industry.
Affymetrix’s service division posted a 37 per cent increase in revenues in Q1 but overall the company slumped, going from $46m (€35m) profit in 2008 to a $25m loss this year.
Google has set up a venture capital fund that will be used to invest in a range of industries, including biotech and healthcare, and is willing to plough tens of millions of dollars into individual companies.
Merck & Co is investing an additional €20m ($27m) in its biologics plant in Carlow, Ireland just weeks after it unveiled plans to create a “powerful biologics presence” through its $41bn move for fellow US drug giant Schering-Plough.
Biotech bodies from around the globe have been calling on their respective governments to provide stimulus packages to compensate for the current difficulties in obtaining credit.
